Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Introduction: We compared the automated Elecsys and manual Innotest immunoassays for cerebrospinal fluid (CSF) Alzheimer's disease biomarkers in a multicenter diagnostic setting. Methods: We collected CSF samples from 137 participants in eight local memory clinics. Amyloid β(1–42) (Aβ42), total tau (t‐tau), and phosphorylated tau (p‐tau) were centrally analyzed with Innotest and Elecsys assays. Concordances between methods were assessed. Results: Biomarker results strongly correlated between assays with Spearman's ρ 0.94 for Aβ42, 0.98 for t‐tau, and 0.98 for p‐tau. Using Gaussian mixture modeling, cohort‐specific cut‐points were estimated at 1092 pg/mL for Aβ42, 235 pg/mL for t‐tau, and 24 pg/mL for p‐tau. We found an excellent concordance of biomarker abnormality between assays of 97% for Aβ42 and 96% for both t‐tau and p‐tau. Discussion: The high concordances between Elecsys and Innotest in this nonacademic, multicenter cohort support the use of Elecsys for CSF Alzheimer's disease diagnostics and allow conversion of results between methods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S., Brundin, L., Comabella, M., Franciotta, D., Frederiksen, J. L., Fleming, J. O., Furlan, R., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c47cc2 · Cited by 845 · cited 4×
“Innotest t-tau (pg/mL), median [IQR] 451 [285, 729] 290 [227, 352] 351 [250, 463] 635 [384, 915]z Elecsys t-tau (pg/mL), median [IQR] 256 [178, 359] 179 [146, 227] 203 [156, 258] 308 [211, 430]z Innotest p-tau (pg/mL), median [IQR] 62 [45, 89] 48 [40, 58] 54 [44, 63] 79 [56, 105]z Elecsys p-tau (pg/mL), median [IQR] 2…”
MethodInfluentialSelf-citationHansson, O., Seibyl, J., Stomrud, E., Zetterberg, H., Trojanowski, J. Q., Bittner, T., Lifke, V., Corradini, V., Eichenlaub, U., Batrla, R., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.010 · Cited by 808 · cited 5×
“Cut-points for the Ab42 Elecsys measurements have been previously reported in three cohorts: 1100 pg/mL in the Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably cohort, 977 pg/mL in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort [21], and 1098 pg/mL in the Knight Alzheimer’s Dise…”
BackgroundMethodResultInfluentialStrategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626
Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
De Meyer, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.179 · Cited by 462 · cited 3×
“MMSE, median [IQR] 26 [24, 29] 29 [28, 30] 27 [25, 29]y 25 [22, 27]z Innotest Ab42 (pg/mL), median [IQR] 644 [525, 1032] 1124 [907, 1269] 747 [557, 1207]* 570 [495, 702]z Elecsys Ab42 (pg/mL), median [IQR] 850 [620, 1403] 1536 [1203, 1971] 973 [641, 1662]* 748 [569, 977]z Elecsys Ab42 above ULOD (%) 27 (20%) 12 (48%)…”
MethodGalasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Bittner, T., Zetterberg, H., Teunissen, C. E., Ostlund, R. E., Militello, M., Andreasson, U., Hubeek, I., Gibson, D., Chu, D. C., Eichenlaub, U., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.09.009 · Cited by 374 · cited 4×
“The fully automated Elecsys assays for CSF Ab42, t-tau CSF, and p-tau (181P) run on the cobas e 601 analyzer (Roche Diagnostics GmbH, Penzberg, Germany), an instrument commonly used in academic hospital laboratories [20].”
BackgroundMethodInfluentialUnbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
Bertens, D., Tijms, B. M., Scheltens, P., Teunissen, C. E., & Visser, P. J. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0233-7 · Cited by 91 · cited 3×
“MMSE, median [IQR] 26 [24, 29] 29 [28, 30] 27 [25, 29]y 25 [22, 27]z Innotest Ab42 (pg/mL), median [IQR] 644 [525, 1032] 1124 [907, 1269] 747 [557, 1207]* 570 [495, 702]z Elecsys Ab42 (pg/mL), median [IQR] 850 [620, 1403] 1536 [1203, 1971] 973 [641, 1662]* 748 [569, 977]z Elecsys Ab42 above ULOD (%) 27 (20%) 12 (48%)…”
MethodSelf-citation
Cited by
Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
Moscoso, A., Grothe, M. J., Ashton, N. J., Karikari, T. K., Rodriguez, J. L., Snellman, A., Suárez-Calvet, M., Zetterberg, H., Blennow, K., Schöll, M., et al. (2021) · Brain · doi:10.1093/brain/awaa399 · Cited by 229
ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project
Ebenau, J. L., Timmers, T., Wesselman, L. M. P., Verberk, I. M. W., Verfaillie, S. C. J., Slot, R. E. R., van Harten, A. C., Teunissen, C. E., Barkhof, F., van den Bosch, K. A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009724 · Cited by 191
Self-citationDas, S., Goossens, J., Jacobs, D., Dewit, N., Pijnenburg, Y. A. L., In ‘t Veld, S. G. J. G., Teunissen, C. E., & Vanmechelen, E. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01212-x · Cited by 50
Self-citationRisk of dementia in APOE ε4 carriers is mitigated by a polygenic risk score
Ebenau, J. L., van der Lee, S. J., Hulsman, M., Tesi, N., Jansen, I. E., Verberk, I. M. W., van Leeuwenstijn, M., Teunissen, C. E., Barkhof, F., Prins, N. D., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12229 · Cited by 26
Self-citationTREM2 risk variants and associated endophenotypes in alzheimer’s disease
Dijkstra, J. I. R., Vermunt, L., Venkatraghavan, V., Ozhegov, G., Coomans, E. M., Ossenkoppele, R., van de Giessen, E., Hulsman, M., de Geus, C. M., van der Flier, W. M., et al. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-025-01700-2 · Cited by 18
Self-citation
Metadata
- Authors
- Willemse, E. A. J., van Maurik, I. S., Tijms, B. M., Bouwman, F. H., Franke, A., Hubeek, I., Boelaarts, L., Claus, J. J., Korf, E. S. C., van Marum, R. J., Roks, G., Schoonenboom, N., Verwey, N., Zwan, M. D., Wahl, S., van der Flier, W. M., & Teunissen, C. E.
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 10
- Issue
- 1
- Pages
- 563-572
- ISSN
- 2352-8729 (ISSN-L)
- OpenAlex
- W2890129631
- Cited by
- 106
- References
- 12
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.